Under-the-radar drug stock has big rebound potential here despite turmoil, says Carter Worth

By CNBC | 6 days ago

Carter Worth suggests AbbVie (ABBV) as a strong buying opportunity due to its recent 25% sell-off and favorable fundamentals. With a lower beta, P/E ratio, and higher dividend yield compared to the market, Worth recommends a price target of $205.

Did you find this insightful?